SYROS PHARMACEUTICALS, INC. Contract with Customer, Asset, after Allowance for Credit Loss, Current
SYROS PHARMACEUTICALS, INC. had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $1.69 million as of 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2023-03-02
- 2022-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $1.69M.
- 2022-09-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $1.77M.
- 2022-06-30: Contract with Customer, Asset, after Allowance for Credit Loss, Current $2.29M.
- 2022-03-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $3.18M.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2022-12-31 | $1.69M 10-K · filed 2023-03-02 |
| 2022-09-30 | $1.77M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.29M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $3.18M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $2.98M 10-K · filed 2023-03-02 |
| 2021-09-30 | $3.63M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $2.18M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.62M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $2.32M 10-K · filed 2022-03-15 |
| 2020-09-30 | $2.31M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.61M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.64M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $158.00K 10-K · filed 2021-03-04 |